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Abstract: Human cytomegalovirus (CMV) infection is the most common cause of perinatal 
viral infection in the developed world, resulting in approximately 40,000 congenitally infected 
infants in the United States each year. Congenital CMV infection can produce varying degrees of 
neurodevelopmental disabilities. The significant impact of congenital CMV has led the Institute 
of Medicine to rank development of a CMV vaccine as a top priority. Vaccine development has 
been ongoing; however no licensed CMV vaccine is currently available. Treatment of preg-
nant women with CMV hyperimmune globulin has shown promising results, but has not been 
studied in randomized controlled trials. Education on methods to prevent CMV transmission, 
particularly among young women of child-bearing age, should continue until a CMV vaccine 
becomes available. The epidemiology, clinical manifestations, prevention strategies, and treat-
ment of CMV infections are reviewed.
Keywords: cytomegalovirus, CMV vaccines, congenital CMV, CMV infection, immuno-
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Introduction
Human cytomegalovirus (CMV) is a ubiquitous beta-herpes virus that leads to congeni-
tal infection in 0.4% to 2.3% of all newborns.1 The risk of intrauterine transmission 
after primary CMV infection during pregnancy approaches 40%, with an increased 
risk of adverse fetal effects if infection occurs during the first half of pregnancy.2 Of 
congenitally infected infants, approximately 10% are symptomatic at birth. Of the 
remaining 90% of infants who are asymptomatic at birth, 10%–15% will subsequently 
manifest evidence of permanent sequelae.3 Congenital CMV is a significant cause 
of neurodevelopmental disability, including sensorineural hearing loss (SNHL) and 
intellectual disability (previously referred to as “mental retardation”). More children 
suffer from long-term sequelae as a result of congenital CMV infection than Down 
syndrome or fetal alcohol syndrome.4 In this review, current concepts regarding the 
epidemiology, pathogenesis, and prevention of CMV infection are summarized, with 
an emphasis on strategies designed to improve awareness of the risk of CMV among 
women of childbearing age.
Epidemiology
CMV is found worldwide, with the rate of seropositivity affected by geographic, 
socioeconomic, and ethnic background.2,3 In developed countries, the prevalence of 
CMV seropositivity is 40% to 60% in individuals of middle to upper socioeconomic 
status and ∼80% among those of lower socioeconomic status.3 By comparison, virtually International Journal of Women’s Health 2010:2 24
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individuals in developing countries have been infected by 
CMV in early childhood.3 In the United States, the serop-
revalence of CMV is higher among non-Hispanic blacks and 
Mexican Americans than among non-Hispanic whites.5
Congenital CMV infection can occur as the result of 
a primary CMV infection, reinfection with a new strain 
of CMV, or reactivation of a latent infection.6,7 Maternal 
immunity to CMV provides some protection against vertical 
transmission of the virus. If a primary CMV infection occurs 
in the period just prior to conception, the risk of transmis-
sion is 8.7%.8 Primary maternal CMV infection occurring 
in the first, second, and third trimester results in congenital 
infection in approximately 25%, 50%, and 75% of fetuses, 
respectively.9 In contrast, the risk of CMV transmission to 
the fetus after a recurrent maternal infection is only 0.15 to 
2%.10,11 Fowler et al demonstrated a 69% reduction in the 
risk of congenital CMV infection in future pregnancies in 
women who were seropositive for CMV when compared to 
seronegative women.12 However, despite the risk reduction 
preconception immunity affords, over 60% of infants with 
congenital CMV infection are born to mothers with immunity 
to CMV prior to pregnancy, reflecting the high rate of CMV 
seropositivity in the population.13 In populations with high 
maternal CMV seropositivity, the incidence of congenital 
CMV infection is greater than in populations of lower mater-
nal seroprevalence.1
It has generally been believed that the fetuses of pregnant 
women with preconception immunity to CMV are somewhat 
protected against the most significant neurodevelopmental 
sequelae of congenital CMV infection. A study comparing 
women with preconception immunity to CMV to those who 
acquired primary CMV infection in pregnancy showed that 
the women with preconception immunity have a significant 
reduction in transmission of CMV to the fetus, as well as 
decreased severity of disease in infected infants.11 In that 
study, 25% of the infants whose mother had a primary infec-
tion had at least one sequela, compared with 8% when the 
infection was recurrent. However, subsequent studies have 
not demonstrated the same degree of protection conferred 
by preconception immunity in congenitally infected infants. 
Boppana et al studied infants with symptomatic congenital 
CMV infection as the result of both primary and recurrent 
maternal infection and found no difference in the severity 
of clinical findings between the two groups.14
Pathogenesis
CMV is a linear double-stranded DNA virus, and its 
genome is comprised of over 250 kilobase pairs. The three 
distinct regions of the CMV virus include the capsid 
containing the viral genome; the tegument layer containing 
phosphoproteins; and an outer lipid envelope containing 
glycoproteins. The capsid, which comprises 162 capsomere 
subunits arranged in icosahedral symmetry, houses the 
viral genome.15 The capsid is surrounded by the tegument 
of the CMV virion. A large number of proteins are located 
in the tegument. These tegument proteins, including phos-
phoprotein 65 (pp65), are some of the most immunogenic 
proteins in the virion, and are the immunodominant targets 
of T-lymphocytes responses to CMV.16,17 Surrounding the 
tegument is the envelope, which contains an as yet incom-
pletely defined number of virally encoded glycoproteins. The 
most abundant glycoproteins include gB complex, gM/gN 
complex, and gH/gL/gO complex. Seropositive individuals 
typically mount a neutralizing antibody response directed 
against these glycoproteins making these protein products 
potentially useful subunit vaccine candidates.18–20
CMV is a complex virus that appears to employ multiple 
strategies to evade the host immune system.21 A healthy, 
immunocompetent individual can control CMV infection, but 
only at great expense to the host immune system: remarkably, 
approximately 10% of both the CD4+ and CD8+ memory 
compartments in blood are specific for CMV-encoded pro-
teins.22 The chronic, persistent nature of CMV, character-
ized by frequent episodes of asymptomatic reactivation and 
shedding, probably contributes to the ability of the virus to 
cause congenital infection even in women with long-standing 
preconception immunity.
Congenital and postnatal 
transmission
Children as source of CMv
Daycare centers are a significant source of CMV infection. 
Children less than three years of age with postnatally acquired 
CMV infection have been demonstrated to excrete CMV in 
their urine and saliva for 6 to 42 months.23 Children enrolled 
in daycare become infected with CMV between 15 and 70% 
of the time.24 Seronegative mothers with children in group 
daycare are at significant risk of acquiring CMV infection, 
with at least 50% of them seroconverting within 1 year of 
their child’s CMV infection.25
Breast-feeding
CMV is excreted in the breast milk of seropositive women.26 
The risk of CMV transmission in infants breast-fed by 
seropositive women shedding virus in their breast milk has 
been reported to be 58% to 69%.27,28 CMV infection acquired International Journal of Women’s Health 2010:2 25
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in the postnatal period in healthy term infants typically is 
asymptomatic, only rarely producing any morbidity. There 
is no evidence that acquisition of CMV via breast milk leads 
to any adverse neurodevelopmental sequelae. In a study of 
CMV transmission through breast-feeding, all of the infants 
who acquired CMV infection had normal neurodevelopment 
at a mean follow-up of 51 months.28
While the safety of breast-feeding has been established 
in term infants in women shedding CMV virus, controversy 
exists on the safety of breast-feeding low birth weight, 
premature infants. Studies in low birth weight and very low 
birth weight preterm infants yield conflicting results with 
respect to the risk of developing symptomatic infection 
following breast milk acquisition of CMV .29 A recent study 
of early postnatal CMV infection in preterm infants in an 
highly immune population demonstrated that symptomatic 
CMV infection was rare.30 Efforts to reduce the infectivity of 
breast milk from seropositive mothers has included freezing 
breast milk at -20 °C, Holder pasteurization, and short-term 
pasteurization.31 Of these methods, freeze-thaw is the best 
studied approach, and the technique most likely to retain 
the salutary immunological properties of breast milk. While 
freezing breast milk does lower the incidence of postnatally 
acquired CMV infection, it does not entirely eliminate the 
risk.32 It remains unclear whether interventions designed 
to interrupt breast milk transmission of CMV to low birth 
weight, premature babies improve either short-term or long-
term outcomes for these infants.
Other
CMV can also be transmitted through close non-sexual 
contact, sexual activity, blood transfusions, and organ trans-
plantation.4 Two methods are currently employed to decrease 
the risks of CMV transmission through blood transfusion, 
including utilizing leukocyte-reduced and CMV-negative 
blood products. Although leukocyte reduction has dramati-
cally reduced the risk of transfusion-associated CMV infec-
tion, reports in the literature are conflicting about whether 
this intervention completely eliminates any risk of transmis-
sion.33,34 A recent survey of the American Association of 
Blood Bank (AABB) physician members showed that 65% 
of those responding felt both leukocyte-reduced and CMV-
negative blood components were equivalent in their ability 
to prevent transfusion transmission of CMV.35 However, 
despite the AABB survey results on attitudes toward leuko-
cyte reduced blood products, fetuses and neonates are more 
likely to receive CMV-negative blood products compared to 
other groups receiving transfusions.35
Clinical manifestations
Maternal CMv
Most CMV infections are subclinical in healthy immuno-
competent hosts.1 When present, clinical symptoms of 
primary CMV infection include flu-like syndrome, fever, 
myalgias, pharyngitis, weakness, and fatigue. Laboratory 
abnormalities can include elevated liver transaminases and 
lymphocytosis. Most studies have shown that pregnancy does 
not appear to affect the clinical course of CMV infection. 
A more recent look at primary CMV infection in pregnancy 
by Nigro et al demonstrated substantially higher rate of 
symptoms associated with CMV infection than previously 
reported.36 In a cohort study, 32 women (31%) diagnosed 
with primary CMV experienced either persistent fever or 
a flu-like illness.36 Practitioners should have a high index 
of suspicion when caring for at risk pregnant women with 
undiagnosed illness or fever.
Congenital CMv
Only 10% of congenitally infected fetuses are symptomatic 
at birth. Clinical symptoms include microcephaly, growth 
restriction, hepatosplenomegaly, chorioretinitis, jaundice, 
petechiae, hearing impairment, thrombocytopenia, hyperbili-
rubinemia, and anemia.13,37 The risk for neurologic sequelae 
is increased when infection occurs in the first trimester.38 
The majority of infants with symptomatic congenital CMV 
infection at birth have evidence of central nervous system 
(CNS) impairment. In a study of 106 infants with symptom-
atic congenital CMV infection, 68% of infants had at least 
one clinical finding suggestive of neurologic impairment.37 
It was reported in the early 1980s that infants with symptom-
atic congenital CMV infection at birth have a 91% chance 
of developing long-term sequelae from the infection, and 
a 29% death rate, although advances in neonatal intensive 
care make mortality much less likely today.39 Of infants with 
asymptomatic congenital CMV infection at birth, 10% to 
15% will go on to develop symptoms, typically manifested 
as SNHL.
Congenital CMV infection is the most common non-
genetic cause of SNHL in children. In the DECIBEL study, 
23% of children with profound SNHL had congenital CMV 
infection.40 Permanent hearing loss occurs in approximately 
14% of children with congenital CMV infection.41 SNHL 
from congenital CMV can present later in childhood. 
Approximately 6% to 23% of children with congenital CMV 
infection who are asymptomatic at birth will subsequently 
develop hearing loss.42 However, symptomatic infection at International Journal of Women’s Health 2010:2 26
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birth appears to be much more likely than asymptomatic 
infection to be associated with delayed SNHL, with a reported 
rate of delayed-onset hearing loss in symptomatic newborns 
of 33.7%.43
Diagnosis
Diagnosis of maternal infection
Diagnosis of maternal primary CMV infection can be chal-
lenging. Maternal primary CMV infection is confirmed if 
there is documented IgG seroconversion; however, most 
women do not have a baseline pre-pregnancy serology for 
comparison. A second method to diagnose primary CMV 
infection is to test for CMV-specific IgM, which is an indica-
tor of recent or active CMV infection. Several problems exist 
with CMV IgM as a screening test. First, CMV IgM can be 
present for up to 9 months after a primary infection.2 Second, 
CMV IgM can be produced in both recurrent infections, as 
well as following reactivation of infection; thus, the finding 
of IgM antibodies does not allow discrimination of the timing 
of infection.44 Third, there is discordance among commer-
cially available kits for CMV IgM, as well as false positive 
results.45 The AxSYM CMV IgM assay is very sensitive when 
compared to other commercial assays.46 A highly sensitive 
IgM assay can identify more pregnancies at risk.
In pregnant women with CMV-specific IgM, anti-CMV 
IgG avidity testing can be utilized to differentiate primary 
CMV infection from reactivation of latent infection or 
reinfection.44 Low avidity indices are indicative of an acute 
or recent primary CMV infection, and persist for approxi-
mately 18 to 20 weeks.44 Lazzarotto et al demonstrated that 
if the CMV IgG avidity index is performed prior to 18 weeks 
gestation, it has 100% sensitivity for detecting pregnancies 
at risk for transmitting CMV to the fetus, however the 
sensitivity is decreased to only 62.5% if the test is performed 
after 20 weeks gestation.47 Additionally, a recent CMV 
infection can be excluded if a high avidity is demonstrated 
in the first 12 to 16 weeks of pregnancy. If high avidity 
antibodies are present in the first trimester, a pregnancy is 
unlikely to result in symptomatic congenital transmission. In 
pregnancies where primary maternal infection is confirmed, 
further evaluation is directed toward determining if the fetus 
is infected (see Figure 1).
Diagnosis of fetal infection
Ultrasound can detect anomalies associated with CMV 
congenital infection, although many of the findings are 
non-specific. Prenatal ultrasonographic findings of con-
genital CMV infection include intrauterine growth restriction 
(IUGR), microcephaly, ventriculomegaly, periventricular 
calcifications, echogenic bowel, hydramnios, hydrops, 
pleural effusion, and placental enlargement.48 The sensi-
tivity of ultrasound to detect congenital CMV infection is 
poor given that the majority of congenitally infected infants 
are asymptomatic. In a study of 600 pregnant women with 
primary CMV infection, abnormal ultrasound findings were 
detected in 51/600 (8.5%) of those pregnancies and in 23/154 
(14.9%) fetuses with documented congenital infection.48 The 
positive predictive value of an abnormal ultrasound predict-
ing symptomatic congenital infection in women with primary 
CMV infection was only 35.3% when fetal infection status 
was unknown, compared to 78.3% when congenital CMV 
infection was confirmed.48
Fetal infection can be diagnosed by documenting the 
presence of CMV in the amniotic fluid (AF), most typically 
demonstrated by PCR analysis (below). Amniocentesis 
should be offered to women with documented serocon-
version, serologic studies suggestive of a primary CMV 
infection, or abnormal ultrasound findings consistent with 
congenital CMV infection. The drawback of definitive testing 
is the risk associated with invasive diagnostic testing. The 
risk of procedure-related pregnancy loss has been demon-
strated to be approximately 1/300 to 1/500.49,50 The risk of 
iatrogenic vertical CMV transmission through amniocentesis 
is minimal.51
The timing of diagnostic testing is important. Amniocen-
tesis for fetal diagnosis of congenital CMV infection should 
be performed after 21 to 23 weeks gestation, and at least 
6 weeks after documentation of primary maternal infection, 
as earlier testing can lead to false negative results.52,53 In 
cases where maternal seroconversion occurs in the first 
trimester, the interval between seroconversion and test-
ing of the AF may need to be increased.52 The timing of 
diagnostic testing is due to the fact that CMV is excreted 
through the fetal urine at detectable levels 6 to 9 weeks after 
maternal infection, and fetal urination is increased after 20 
to 21 weeks gestation. When testing AF  6 weeks after 
maternal infection and 23 weeks gestation the sensitivity 
of prenatal diagnosis of congenital CMV infection increased 
from 45% to 55% to 95.5%.52
AF can be evaluated with CMV viral culture and CMV 
polymerase chain reaction (PCR). The drawback of viral 
culture is that it can yield false negative results, and it 
requires a lengthy period of time to grow the virus in the 
laboratory (up to 6 weeks). PCR of the AF to detect CMV 
has a sensitivity and specificity of 90% to 98% and 92% to 
98%, respectively.54 Studies attempting to determine the International Journal of Women’s Health 2010:2 27
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Figure 1 Suggested guidelines for management and counseling of women with primary cytomegalovirus (CMv) infection during pregnancy.   While no single maternal test is 
diagnostic, they can be useful in aiding further management and counseling of pregnant women with suspected primary CMV infection. Fetal ultrasound and definitive diagnostic 
testing for congenital infection should be offered when primary maternal CMv infection is suspected.
Fetal ultrasound
Amniocentesis for CMV culture and PCR if  ≥22 weeks gestation 
and ≥6 weeks from symptom onset52 
Normal ultrasound
Negative CMV PCR Positive CMV PCR
Other etiology for 
ultrasound abnormality
Poor fetal prognosis
78% risk of symptomatic
CMV infection48
Negative CMV PCR Positive CMV PCR
Minimal fetal risk 10% symptomatic infection
90% asymptomatic
Abnormal ultrasound
Primary Maternal CMV Infection
• Symptomatic illness compatible with CMV
• Positive IgM antibody
• Low IgG avidity
• Maternal DNAemia
threshold of CMV viral load that is predictive of symp-
tomatic congenital infection and/or sequelae have yielded 
conflicting results. Lazzarotto et al demonstrated that if 
the AF viral load is 103 copies/mL the risk for congeni-
tal infection is 100%, and that the presence of viral load 
of 105 copies/mL is predictive of symptomatic congenital 
infection.55 Additionally, Lazzarotto et al found that an AF 
PCR level of 500 copies/mL is unlikely to be associated 
with symptomatic congenital infection.54 Other studies have 
not demonstrated clear viral load cut-offs correlating with 
fetal outcomes.56,57 While the viral load is generally greater 
in symptomatic infections when compared to asymptomatic 
infections, considerable overlap exists.54,56 The analysis of 
viral load by PCR is also fraught with uncertainty given that 
there are a great number of PCR assays, differing in primer 
sequence, method of PCR, and technique for quantification. 
If the AF CMV PCR and viral culture are negative, then 
congenital CMV infection is unlikely.
Counseling women with primary CMV infection accu-
rately in pregnancy is important. Guerra et al demonstrated 
that accurate interpretation and counseling of women with 
positive CMV screening can decrease the rate of termination 
of pregnancy.58 Women with no evidence of CMV infection 
in the AF are likely to have an uninfected neonate. Women 
with CMV present in the AF should be counseled that there 
is a 10% risk of symptomatic congenital infection and a 90% 
chance of an asymptomatic congenital infection at birth. 
However, if the primary maternal CMV infection occurred in 
early pregnancy, the risk of an infected fetus demonstrating 
symptoms at birth is increased to between 20% and 30%.38,59 International Journal of Women’s Health 2010:2 28
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Fetuses with documented congenital CMV infection and 
ultrasound abnormalities have a poor prognosis, especially 
if cerebral abnormalities are detected.60
Postnatal diagnosis of congenital infection
In the evaluation of a newborn infant with possible congenital 
CMV , care must be taken to not rely on antibody titers in the 
infant (so-called “TORCH” titers) because these are seldom 
of value in establishing the diagnosis of congenital CMV . The 
finding of CMV antibodies in an infant may simply reflect 
transplacental transfer of IgG, and IgM assays are fraught 
with the same issues regarding sensitivity and specificity in 
the newborn as they are in the mother.44,45 The most important 
diagnostic studies in the evaluation of suspected CMV disease 
are virologic studies, not serologic studies, including viral 
culture and PCR. CMV may be cultured from virtually any 
body fluid or organ system. Blood, urine, saliva, cerebrospinal 
fluid, bronchoalveolar lavage fluid, and tissues from biopsy 
specimens are all appropriate specimens for culture. The 
specimen is inoculated on to human cells (usually human 
foreskin fibroblasts) and the cell culture is monitored for the 
development of the characteristic CMV-associated cytopathic 
effect. CMV may grow slowly in culture, requiring up to 
6 weeks of incubation. Culture identification is enhanced by 
centrifugation techniques, followed by monoclonal-antibody 
detection, referred to as the “shell-vial” assay. PCR amplifica-
tion of CMV DNA from clinical specimens is a useful adjunct 
to culture techniques, and in recent years is increasingly being 
employed in place of viral culture for diagnosis of CMV 
infection.54 The information derived from PCR not only helps 
establish the diagnosis of CMV infection, but quantitative 
data may be of value in establishing prognosis, since there 
is evidence that infants with higher viral loads may portend 
an increased risk of development of SNHL; these infants, 
accordingly, may be more likely than infants with low viral 
load to benefit from antiviral therapy with ganciclovir.61
CMV screening
Maternal CMv screening
Routine maternal screening for CMV infection is controver-
sial. Currently neither the American College of Obstetricians 
and Gynecologists (ACOG) nor the Centers for Disease 
Control and Prevention (CDC) recommend routine sero-
logic screening for CMV infection in pregnancy.62,63 Several 
problems exist with routine maternal serologic screening for 
CMV . First, if maternal immunity to CMV is documented, 
it does not rule out the possibility of congenital CMV infec-
tion through infection with a new CMV strain or reactivation 
of maternal CMV . Second, diagnosis of an in utero CMV 
infection does not necessarily predict symptomatic disease 
or sequelae in the infant upon completion of the pregnancy.   
Third, there is no established, evidence-based treatment avail-
able for fetal CMV infection in the pregnant patient. Finally, 
maternal screening may produce undue anxiety, particularly 
if screening is performed without adequate counseling to 
educate the patient about the implications of a positive or 
negative screening test.
Another consideration in developing a CMV screening 
program is the cost-effectiveness of such measures. Cahill 
et al evaluated the cost-effectiveness of 3 screening strategies 
and found that universal screening for primary maternal CMV 
infection would be cost effective if treatment of affected 
pregnancies with CMV specific hyperimmune globulin 
(HIG) would result in a minimum of a 47% reduction in 
symptomatic CMV disease.64 Further studies with random-
ized controlled trials are needed to evaluate treatment options, 
including CMV HIG, to determine a screening program’s 
ability to reduce morbidity of congenital CMV disease.
Until evidence-based treatment is available, efforts 
should be made on emphasizing preventative measures to 
all women who are attempting pregnancy, or who are cur-
rently pregnant. Screening of pregnant women should be 
limited to instances where there is a clinical suspicion of an 
active CMV infection, either due to maternal symptoms, or 
ultrasonographic abnormalities suggesting fetal anomalies 
or maldevelopment.
Neonatal CMv screening
Newborn screening (NBS) for endocrine and metabolic dis-
orders has been successfully performed through collection 
and analysis of dried blood spot (DBS) specimens. Universal 
newborn hearing screening (UNHS) is currently employed 
and has been demonstrated to have a positive effect on lan-
guage outcomes among children with permanent bilateral 
hearing loss.65
Congenital CMV infection is a known cause of SNHL; 
however, UNHS will miss up to 75% of cases of CMV-associ-
ated SNHL, since, as noted, hearing loss may be late-onset. 
This observation provides support for the concept of universal 
screening for congenital CMV .
Utilization of NBS for diagnosis of congenital CMV 
infection is currently being debated. NBS for CMV can 
be justified based the much higher incidence of congenital 
CMV infection than many other disorders included in NBS 
program, and its association with SNHL. The potential benefit 
of NBS for congenital CMV derives from the opportunity to International Journal of Women’s Health 2010:2 29
Prevention of maternal cytomegalovirus infection Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
identify children who require close surveillance, including 
audiological evaluation and neurodevelopmental assessment. 
Early intervention programs for SNHL and developmental 
concerns can then be instituted, if required. Since the major-
ity of cases of SNHL associated with congenital CMV occur 
post-natally, as already noted, a normal NHS does not provide 
complete reassurance in an infant with congenital infection, 
and serial audiological evaluation is required. Additionally, 
screening could identify children who may benefit from 
antiviral treatment to prevent hearing loss.
Prior to the implementation of universal CMV screen-
ing, a sensitive, reliable, and cost effective screening test 
for CMV needs to be optimized needs to be established. 
CMV testing can be performed utilizing urine, saliva, or 
DBS. Viral culture of the urine has long been the gold 
standard laboratory test for the diagnosis of CMV infection 
in newborns. Given the time-consuming and costliness of 
viral culture, PCR has been increasingly utilized to detect 
CMV virus. PCR of DBS has recently been reported by a 
number of investigators as a useful technique for detecting 
congenital CMV infection. One objection to the use of DBS 
as the sole test for detecting congenital CMV is that the viral 
load in blood may often be lower than in saliva or urine, or 
that DNAemia may be absent altogether in a congenitally 
infected baby. This may make detection of DNA in the 
DBS relatively insensitive compared to urine or saliva in 
making the diagnosis of congenital CMV.66 There have 
been many studies evaluating varying methods for CMV 
DNA detection by PCR with a wide range of sensitivities 
reported.67–69 Continued work toward identification of the 
optimal screening test is necessary.
Another hurdle in the development of a NBS program 
for CMV is the creation and oversight of programs to carry 
out screening. Two of the options that have been posed for 
congenital CMV NBS are 1) hospital-based program utilizing 
urine, saliva, or DBS specimens and 2) state NBS program 
using DBS.70
Before universal NBS for congenital CMV can become 
standard practice, a reliable and sensitive screening test 
needs to be identified, mechanisms for implementation of 
this screening test must be validated, and a plan for how to 
longitudinally monitor children indentified with congenital 
CMV through screening needs to be identified.
Prevention
Prevention of CMV transmission in women of childbear-
ing age is of utmost importance in order to reduce the rate 
of congenital infection. Both the CDC workgroup and 
ACOG recommend education on hygienic practices to 
prevent CMV viral transmission.62,71 Hygienic strategies are 
important in preventing CMV transmission given that the 
saliva and urine of infected children are significant sources 
of CMV infection among women who are pregnant.25 Pre-
ventative strategies include washing hands whenever there 
is contact with a child’s saliva or urine, not sharing food, 
utensils, or cups, and not kissing a child on the mouth or 
cheek.4,72
Education of women about the implications of acquir-
ing CMV infection, particularly during pregnancy, is vital. 
A survey of women in 2005 showed that only 14% of 
women knew what CMV was, but reported that following 
preventative measures for preventing an infection that could 
harm an unborn baby would generally be acceptable.73 The 
effectiveness of educating pregnant women on methods to 
prevent CMV transmission has been demonstrated.74–76 In 
a study where seronegative mothers with a child in group 
day care were instructed on measures to prevent CMV 
transmission, pregnant mothers had a significantly lower 
rate of CMV infection when compared to non-pregnant 
mothers attempting conception.75 Additionally, Vauloup-
Fellous et al recently demonstrated a lower CMV serocon-
version rate after counseling pregnant women on hygienic 
measures.76,77
Despite the demonstrated success of education of preg-
nant women on hygienic measures to prevent CMV trans-
mission, obstetricans are not providing uniform, appropriate 
counseling. A recent survey of the ACOG Collaborative 
Ambulatory Research Network (CARN) members revealed 
that less than half counseled their patients on methods to 
prevent CMV transmission and the importance of prevention 
of transmission.63 Additionally, results of the survey of the 
ACOG CARN members and a survey of physicians in the 
Netherlands demonstrated gaps in their knowledge of CMV 
transmission.63,78 Continued education of providers on CMV 
infection and prevention is important in order for accurate 
counseling of pregnant women.
Effective strategies to increase awareness of CMV and the 
methods to prevent its transmission are needed. Additionally, 
a systematic means to measure the success of these programs 
is required. Recently, Bate and Cannon have proposed a plan 
to identify effective behavioral interventions for prevention 
of congenital CMV based on a social marketing model.79 
This paper provides a framework to identify and evaluate 
behavioral interventions aimed at encouraging pregnant 
women to follow preventative measures.79 Identification of 
effective means to educate pregnant women on CMV would International Journal of Women’s Health 2010:2 30
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allow for more focused use of resources, and could result in 
a reduction in CMV transmission.
Therapy
Antiviral
Antiviral agents currently licensed for the treatment of CMV 
infections include ganciclovir and its prodrugs valganciclo-
vir, foscarnet, and cidofovir. Although there has been sig-
nificant experience with the use of ganciclovir in the infected 
newborn (reviewed below), none of these agents have been 
formally approved by the US Food and Drug Administration 
(FDA) specifically for the treatment or prevention of CMV 
infections during pregnancy or for congenital CMV .80 There 
has been concern reported regarding the safety of treatment 
with antiviral medications in pregnancy. A case report of use 
of oral ganciclovir in a liver transplant patient in pregnancy 
did not show any evidence of teratogenicity.81 Ganciclovir 
has been demonstrated to cross the placenta, and therefore 
could in theory, be utilized to treat in utero congenital 
CMV infection.82 An observational study of 20 women with 
21 fetuses with confirmed in utero CMV infection treated 
with oral valacyclovir demonstrated placental transfer of the 
drug, with therapeutic concentrations in the AF and a reduc-
tions of viral load in the fetal blood.83 There have been several 
case reports of treatment of congenital CMV infection in 
utero with oral, parenteral, or intra-amniotic ganciclovir with 
varying degrees of success.84–88 Although it is probably safe, 
prenatal treatment of fetal CMV infection with ganciclovir is 
currently not supported by the available data; further study 
with a randomized controlled trial is needed.
Despite a lack of formal FDA approval, there is good 
evidence supporting the treatment of congenital CMV infec-
tion with ganciclovir, based upon its demonstrated impact 
on SNHL outcomes. A randomized, controlled trial of 100 
neonates with symptomatic congenital CMV infection treated 
with intravenous ganciclovir at a dose of 6 mg/kg every 12 
hours for 6 weeks showed prevention of deterioration of 
hearing at 6 months.89 In a retrospective review of 9 children 
with symptomatic congenital CMV , none had progression of 
hearing loss following prolonged ganciclovir therapy.90 In 
another study, children with asymptomatic congenital CMV 
infection were treated with ganciclovir versus observation 
and followed over time.91 No children in the ganciclovir 
group had SNHL, while 11.1% in the observation group 
demonstrated evidence of SNHL over time. Valganciclovir 
has been more recently studied for the postnatal treatment of 
symptomatic congenital CMV , and is an attractive alterna-
tive to ganciclovir, because it can be administered orally.92 
A trial is currently in progress comparing treatment with 
valganciclovir for 6 weeks versus 6 months, with the goal 
of examining whether prolonged therapy further improves 
neurodevelopmental outcomes, including SNHL.92
Passive immunization
Immunoglobulin therapy has been used to treat several 
conditions in pregnancy and is generally well tolerated. The 
mechanisms by which immuoglobulins act to treat many 
pregnancy-related conditions remain largely unknown. Treat-
ment of a variety of viral infections with immunoglobulin has 
been valuable in disease control. Theoretical mechanisms 
include direct neutralization of virus particles; facilitation 
of antibody-directed natural killer cell activity; antibody-
dependent cellular cytotoxicity; and blocking of viral entry 
at the cell surface.93
Passive immunization with hyper-immune globulin (CMV 
HIG) has been studied for the in utero treatment and preven-
tion of congenital CMV infection. CMV HIG is a pooled, 
high-titer immunoglobulin preparation derived from donors 
with high levels of CMV antibody. Improved perinatal out-
comes after treatment of congenital CMV infection was first 
demonstrated in animal models.94,95 Nigro and colleagues 
completed a prospective study of CMV HIG for the treatment 
of pregnant women with primary CMV infection, including 
some women with confirmed fetal CMV infection.96 The 
women were enrolled in the “therapy” group if they had an 
amniocentesis and confirmed congenital CMV infection, as 
evidenced by a positive PCR in the AF, or the “prevention” 
group if they did not have an amniocentesis. In the therapy 
group only 1/31 of the treated mothers delivered an infant 
with congenital CMV disease, compared to 7/14 mothers who 
were not treated with HIG. In the prevention group 6/37 moth-
ers receiving HIG delivered infants with congenital CMV , 
compared to 19/47 mothers who did not receive treatment. 
Overall, there was a statistically significant reduction of risk 
for congenital CMV infection in the HIG therapy group, and 
a reduction in CMV infection in the HIG prevention group. In 
a subsequent study by Nigro and colleagues, 3 fetuses treated 
with HIG had resolution of their ultrasonographically detected 
cerebral abnormalities; in contrast 2 untreated fetuses had 
persistence of their cerebral abnormalities.97
In addition to fetal effects, CMV HIG has been demon-
strated to affect the placenta. In pregnancies treated with 
HIG there has been demonstration of significant reduc-
tions in placental thickness.97,98 The reduction in placental 
thickness observed following HIG treatment suggests that 
improved fetal outcomes are mediated, at least in part, International Journal of Women’s Health 2010:2 31
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through improved placental health and function, and not 
(only) through the salutary effect of immune globulin present 
in the fetal circulation.99
The mechanisms by which HIG works for the treatment 
and prevention of congenital CMV may be due to the virus 
neutralizing effect. Nigro et al demonstrated that women in 
the treatment group had significantly higher levels of CMV 
specific IgG concentration and IgG avidity after HIG treat-
ment when compared to the untreated group.96 Symptomatic 
CMV disease may be secondary to inflammation in response 
to CMV infection.100,101 The immunomodulatory effects of 
HIG may decrease the inflammation, and subsequent tissue 
damage from CMV . Randomized controlled trials of HIG 
for treatment and prevention of congenital CMV infection 
are needed. Until such data are available, clinicians could 
give consideration to treatment with CMV HIG in pregnant 
patients with confirmed fetal CMV infection.
Vaccines
Live attenuated virus vaccines
It has been over three decades since the first live CMV vac-
cine candidate was tested in humans.102 A subsequent live 
attenuated CMV vaccine candidate, the Towne strain, was 
found to have a good safety profile and was immunogenic.103 
A clinical trial of the Towne strain CMV vaccine in kidney 
transplant patients showed that the vaccine did not prevent 
CMV infection, but it did reduce the severity of CMV 
disease when compared to placebo controls.104 However, the 
Towne vaccine failed to prevent CMV infection in seronega-
tive women who had children attending group day care when it 
was tested in a placebo-controlled trial.105 The lack of efficacy 
in this study was attributed to the decreased neutralizing titers 
produced after Towne vaccination when compared to infec-
tion by wild type virus. In addition, the laboratory-adapted 
Towne strain of CMV has genomic deletions which may affect 
the immunogenicity of the vaccine. With the goal of improv-
ing the immunogenicity of live, attenuated CMV vaccines, 
4 “chimeric” vaccines were created which represented hybrids 
of the Towne strain and the less attenuated Toledo strain of 
CMV , and tested in a phase one study; these vaccines were 
all well tolerated, although immunogenicity was difficult to 
assess.106 Additional study of the chimeric vaccines need to 
be performed in seronegative controls.
Subunit vaccines
Purified recombinant glycoprotein B
Additional vaccine approaches are currently being developed 
with the goal of inducing a potent virus-neutralizing antibody 
response.107 The CMV envelope glycoprotein B (gB) has 
been the most studied subunit vaccine candidate for this 
purpose, since it is a target of neutralizing antibody in all 
CMV-seropositive individuals. Animal models of gB vaccine 
have shown its ability to prevent congenital CMV infection 
and disease.108,109 Results of a phase II, placebo-controlled, 
randomized, double-blind trial of the recombinant CMV 
envelope gB with MF59 adjuvant were recently published.110 
In this study, three doses of the CMV vaccine or placebo were 
administered at 0, 1, and 6 months to healthy women within 
12 months postpartum. Women in the vaccine group were 
less likely to become infected with CMV than the placebo 
group (P = 0.02) with 18/225 women becoming infected 
with CMV in the vaccine group, compared to 31/216 in the 
placebo group.
DNA vaccines
DNA vaccines have been studied in both animal models 
and humans. In the guinea pig model gB DNA vaccination 
administered prior to conception offered some protection 
against congenital CMV transmission in the liveborn pups.111 
A phase I study of a bivalent CMV DNA vaccine demon-
strated safety and immunogenicity of the DNA vaccine.112 
The effect of immune priming with a CMV DNA vaccine 
encoding pp65, IE1, and gB was tested by administering the 
Towne strain after vaccination and evaluating the immune 
response.113 There was a significant decrease in time to pp65 
T-cell and gB antibody response in DNA primed subjects 
when compared to control subjects who were administered 
Towne strain only. DNA vaccines are currently being 
evaluated in the hematopoietic stem cell transplantation 
population toward the goal of reducing CMV disease in these 
individuals.114
vector systems
Vector systems utilize non-replicating vectors to express gene 
products of interest. Two examples of vector systems utilized 
in CMV vaccine development are the modified vaccinia 
virus Ankara (MVA) and an alphavirus vector based on an 
attenuated variant of Venezuelan equine encephalitis virus. 
MVA utilizes a highly attenuated poxvirus vector. The MVA 
vector system can express gB, as well as the cell-mediated 
immunity targets pp65, and IE1.115 The alphavirus vector 
system produces virus-like replicon particles (VRP) that can 
express gB, pp65 and IE1.116 The alphavirus vector system 
has been studied in the in the guinea pig model and was found 
to induce both humoral and cellular immunity and improve 
pregnancy outomes.117International Journal of Women’s Health 2010:2 32
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Future prospects
Recent advances in the understanding of CMV-cell interac-
tions have lead to new insights into potential glycoprotein 
targets for vaccination. Recently, a new glycoprotein com-
plex, including the gene products of the UL128-131 region of 
the viral genome, has been characterized. These proteins are 
necessary for CMV entry into epithelial cells.118,119 The live, 
attenuated Towne vaccine and the gB-based protein subunit 
vaccine are less effective than natural infection in inducing 
antibodies capable of neutralizing CMV infection in epithe-
lial cells.  Future optimization of CMV vaccines may require 
improvement in the humoral response to virally encoded 
proteins important in epithelial cell entry, particularly in 
view of the fact that most CMV infections are acquired at 
mucosal surfaces.120
Conclusion
CMV remains a significant public health concern. The neu-
rologic disability from congenital CMV infection can be 
devastating. Antiviral drugs administered postnatally appear to 
decrease the severity of SNHL. CMV HIG has shown promis-
ing results for in utero treatment of fetal CMV infection, and 
possible prevention of congenital transmission, although ran-
domized, blinded, controlled trials are lacking. CMV vaccine 
development continues to be a major public health priority.   
Until an effective CMV vaccine is licensed, education of young 
women regarding hygienic and behavioral approaches that can 
help prevent CMV transmission is essential.  Obstetricians can 
lead the way in ensuring that appropriate counseling about the 
risks of CMV becomes a mainstay of prenatal care.
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